2 active not recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Sham Administration: new trials by email Literature Review of Sham Administration trials Research Report on Sham Administration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Vonaprument, Sham Administration - Geographic Atrophy | Phase 3 | Active not recruiting | Annexon, Inc. | 659 | 2024-07-30 | 2026-10-06 |
| AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension AGN-193408 SR, Lumigan, Sham Administration - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | AbbVie | 100 | 2020-11-16 | 2026-05-22 |
Geographic Atrophy (1) · Glaucoma, Open-Angle (1) · Ocular Hypertension (1)
AbbVie (1) · Annexon, Inc. (1)
United States (2) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Spain (1) · United Kingdom (1)